CONMED CORPORATION Amortization of Other Deferred Charges
CONMED CORPORATION (CNMD) reported Amortization of Other Deferred Charges of $29.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherAmortizationOfDeferredCharges · last filed 2026-07-29
- CONMED CORPORATION amortization of other deferred charges for the quarter ending 2025-12-31 was $14.78M, a 7.08% increase year-over-year.
- CONMED CORPORATION amortization of other deferred charges for the quarter ending 2025-09-30 was $14.23M, a 3.28% increase year-over-year.
- CONMED CORPORATION amortization of other deferred charges for the quarter ending 2025-06-30 was $14.11M, a 3.15% increase year-over-year.
- CONMED CORPORATION amortization of other deferred charges for the quarter ending 2025-03-31 was $14.02M, a 0.19% increase year-over-year.
- CONMED CORPORATION amortization of other deferred charges for fiscal 2025 was $57.14M, a 3.41% increase from fiscal 2024.
- CONMED CORPORATION amortization of other deferred charges for fiscal 2024 was $55.25M, a 0.76% decline from fiscal 2023.
- CONMED CORPORATION amortization of other deferred charges for fiscal 2023 was $55.67M, a 4.13% increase from fiscal 2022.
- CONMED CORPORATION amortization of other deferred charges for fiscal 2022 was $53.46M, a 1.45% decline from fiscal 2021.
| Period end | Amortization of Other Deferred Charges 3 month | Amortization of Other Deferred Charges 6 month | Amortization of Other Deferred Charges 9 month | Amortization of Other Deferred Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.63M 10-Q · filed 2026-07-29 | |||
| 2025-12-31 | $14.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $29.02M derived: sum of 2 quarters · filed 2026-02-17 | $43.12M derived: sum of 3 quarters · filed 2026-07-29 | $57.14M 10-K · filed 2026-02-17 |
| 2025-09-30 | $14.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $28.34M derived: sum of 2 quarters · filed 2026-07-29 | $42.35M 10-Q · filed 2025-11-06 | $56.16M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $14.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $28.12M 10-Q · filed 2026-07-29 | $41.93M derived: sum of 3 quarters · filed 2026-07-29 | $55.71M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $14.02M 10-Q · filed 2025-05-01 | $27.82M derived: sum of 2 quarters · filed 2026-02-17 | $41.60M derived: sum of 3 quarters · filed 2026-02-17 | $55.28M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-12-31 | $13.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $27.59M derived: sum of 2 quarters · filed 2026-02-17 | $41.26M derived: sum of 3 quarters · filed 2026-02-17 | $55.25M 10-K · filed 2026-02-17 |
| 2024-09-30 | $13.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $27.45M derived: sum of 2 quarters · filed 2025-11-06 | $41.45M 10-Q · filed 2025-11-06 | $55.40M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $13.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $27.67M 10-Q · filed 2025-07-31 | $41.62M derived: sum of 3 quarters · filed 2026-02-17 | $55.56M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $13.99M 10-Q · filed 2025-05-01 | $27.94M derived: sum of 2 quarters · filed 2026-02-17 | $41.89M derived: sum of 3 quarters · filed 2026-02-17 | $55.79M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $13.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $27.90M derived: sum of 2 quarters · filed 2026-02-17 | $41.80M derived: sum of 3 quarters · filed 2026-02-17 | $55.67M 10-K · filed 2026-02-17 |
| 2023-09-30 | $13.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $27.85M derived: sum of 2 quarters · filed 2024-10-31 | $41.72M 10-Q · filed 2024-10-31 | $55.43M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $13.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $27.78M 10-Q · filed 2024-08-01 | $41.49M derived: sum of 3 quarters · filed 2025-02-18 | $55.18M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $13.88M 10-Q · filed 2024-04-25 | $27.59M derived: sum of 2 quarters · filed 2025-02-18 | $41.28M derived: sum of 3 quarters · filed 2025-02-18 | $54.54M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $13.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $27.40M derived: sum of 2 quarters · filed 2025-02-18 | $40.66M derived: sum of 3 quarters · filed 2025-02-18 | $53.46M 10-K · filed 2025-02-18 |
| 2022-09-30 | $13.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $26.95M derived: sum of 2 quarters · filed 2023-10-26 | $39.75M 10-Q · filed 2023-10-26 | $53.26M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $13.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | $26.07M 10-Q · filed 2023-07-27 | $39.57M derived: sum of 3 quarters · filed 2024-02-28 | $53.00M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $12.80M 10-Q · filed 2023-04-27 | $26.30M derived: sum of 2 quarters · filed 2024-02-28 | $39.73M derived: sum of 3 quarters · filed 2024-02-28 | $53.53M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $13.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $26.93M derived: sum of 2 quarters · filed 2024-02-28 | $40.73M derived: sum of 3 quarters · filed 2024-02-28 | $54.25M 10-K · filed 2024-02-28 |
| 2021-09-30 | $13.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $27.23M derived: sum of 2 quarters · filed 2022-10-27 | $40.75M 10-Q · filed 2022-10-27 | $54.35M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $13.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $27.32M 10-Q · filed 2022-07-28 | $40.92M derived: sum of 3 quarters · filed 2023-02-21 | $54.51M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $13.52M 10-Q · filed 2022-05-05 | $27.13M derived: sum of 2 quarters · filed 2023-02-21 | $40.71M derived: sum of 3 quarters · filed 2023-02-21 | $54.32M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $13.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $27.19M derived: sum of 2 quarters · filed 2023-02-21 | $40.80M derived: sum of 3 quarters · filed 2023-02-21 | $54.58M 10-K · filed 2023-02-21 |
| 2020-09-30 | $13.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $27.20M derived: sum of 2 quarters · filed 2021-10-28 | $40.97M 10-Q · filed 2021-10-28 | $55.77M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $13.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $27.39M 10-Q · filed 2021-07-29 | $42.19M derived: sum of 3 quarters · filed 2022-02-22 | $55.57M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $13.78M 10-Q · filed 2021-04-29 | $28.57M derived: sum of 2 quarters · filed 2022-02-22 | $41.95M derived: sum of 3 quarters · filed 2022-02-22 | $55.20M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $28.18M derived: sum of 2 quarters · filed 2022-02-22 | $41.43M derived: sum of 3 quarters · filed 2022-02-22 | $53.63M 10-K · filed 2022-02-22 |
| 2019-09-30 | $13.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $26.63M derived: sum of 2 quarters · filed 2020-10-29 | $38.84M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $13.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $25.46M 10-Q · filed 2020-07-30 | ||
| 2019-03-31 | $12.21M 10-Q · filed 2020-04-30 | |||
| 2018-12-31 | $42.23M 10-K · filed 2021-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |